In clinical trials, longitudinal data are often analyzed using T-tests, anovas or ancovas instead of the more powerful linear mixed models. The purpose of this paper is to demonstrate how the more sophisticated linear mixed models according to the approach of Singer and Willett, which allows special insight into the behaviour of the data, can be used in clinical trials. Individual trajectories of PANNS-MNS Scores from a controlled clinical trial were used to demonstrate all the steps needed for an analysis of longitudinal data. The model is built step by step, model assumptions are checked, time-variant and time-invariant factors are included and the results are interpreted. The unique needs of a clinical trial, such as the calculation of effect sizes or of an appropriate sample size, are taken into account. Finally, a flow chart is presented that would serve as an instruction tool for the analysis of longitudinal data in clinical trials.
INTRODUCTION
Longitudinal data are often collected in clinical trials. For the analysis of these data, however, crosssectional methods are used, which explains why, when data was collected, e.g., at 10 time-points, it is only the first and last values which are used in an analysis of covariance despite using appropriate methods. Failing that means power is lost for the analysis and money is also lost because unused data were collected in vain.
As far back as the 1920s the so called "slope-asoutcome" and "intercept-as-outcome" models were introduced. These models build up the intercept and the slope of a regression equation by means of a regression coefficient and an error term. This makes it possible to consider complex data and error structures and a hierarchical data ordering [1] .
Primarily these methods were introduced for hierarchical data, e.g., data could be grouped *Address correspondence to this author at the Center for Pediatric Clinical Studies, Biometry University Children's Hospital Tuebingen, Frondsbergstraße 23, 72070 Tübingen, Germany; Tel: 0049-7071-2989111; Fax: 0049-7071-294857; E-mail: corinna.engel@med.uni-tuebingen.de according to siblings in families, or students in classes, and so on, as discussed [2] . Before the concept was created, however, the only correct method for analyzing longitudinal data was by means of estimations of individual regression equations. That means the individual measurements were grouped according to the individual involved, thus mirroring reality, as being described [3, 4] . Later on, ideas were proposed to evaluate the influence of specific factors on the course of the data [5] . These methods have been implemented for several years in standard statistical software programmes, e.g. as the procedure "proc mixed" in SAS since 1997, as described in SAS/STAT Software 1997 [6] .
Nevertheless, these methods are still rarely used in the analysis of clinical trials. Recent literature includes analyses of longitudinal data using the t-test [7] or various kinds of analysis of variance as used [8] [9] [10] [11] [12] , as an example. If linear mixed models are used, the model building is usually not described in a manner, that is easy to follow [13] [14] [15] [16] [17] [18] . There even seems to be a trend to regard longitudinal data in a similar way as survival data and to define a certain event out of the measurements that may occur or not, as done [19] [20] [21] , as an example. In particular, the possibility of including time-variant factors in linear mixed models offers a wide field of applications, as in analysing the influence of stress on ward and whether doctors' workload impact supervision and ward activities of final-year students [22] .
Well-established methods like analysis of variance, t-test or survival analysis offer the great advantage that all the necessary tools for planning and analyzing a study are implemented in standard software.
The problems that may arise when more sophisticated and, therefore, more appropriate methods are used in clinical studies, start with the calculation of an adequate sample size, continue with the build-up of an appropriate model and end with the calculation of effect sizes comparable to already known ones.
Based on the statistical analysis of a randomized clinical trial we will show how clinical studies in which quantitative longitudinal data is collected for measuring the outcome can be analyzed using appropriate methods. The approach of Singer and Willett (2003) [23] was chosen, because it facilitates insight in each step of the model building process in a very demonstrative manner applying the principle of multilevel analysis to longitudinal data. This is in contrast to the approach described for instance in SAS/STAT Software 1997 [6] regarding longitudinal data basically as repeated measurements.
We will demonstrate how model building can be done and effect sizes can be calculated. We conclude with a general flow chart which illustrates the analysis up to the final model. Finally, we propose a procedure for the sample size estimation by reviewing the literature.
MATERIAL AND METHODS
In the TONES study [24, 25] , a multicenter clinical trial, 198 patients suffering from schizophrenia were recruited by three separate German centers. The primary endpoint of the study was the improvement of negative symptoms, which was quantified using a modified negative syndrome scale (PANNS-MNS) which is a subscale of the Positive and Negative Syndrome Scale (PANNS). The PANSS is an observer based rating scale for the assessment of symptoms associated with psychotic disorders and is based on a structured clinical interview. The PANSS includes three subscales: "Positive Symptoms", "Negative Symptoms", and "General Psychopathology". All the scales showed a sufficient fit with normal distribution for the use of parametric methods, as has been shown [26] . According to Klingberg et al. (2006) [27] , a modified negative symptom scale has been chosen as primary endpoint. The TONES study compares the efficacy of two different psychological interventions: cognitive behavioural therapy (CBT), which is recommended in evidence based treatment guidelines for the reduction of positive symptoms, and cognitive remediation (CR). CR has been chosen as comparator as published evidence did not indicate treatment effects for negative symptoms at the time of designing this study. An effect size of 0.35 points superiority of CBT at the end of the study was expected. Sample size calculation was based on this assumption ( =0.05, ß=0.2) and done for classical ANOVA due to the fact, that software for the calculation of sample size for the analysis of longitudinal data using multilevel mixed model was not available. The design and sample size calculation of the study and the results of the primary and secondary endpoints were published [24, 25] .
The therapeutic alliance proved to be a common ingredient of all psychotherapeutic interventions and to be at least modestly correlated with outcome [28] . Thus, ratings of the therapeutic alliance were assessed at the end of each session of the study therapies using items from the short versions of the Bernese PostSession Report for patients (BPSR-P) developed by Grawe and his co-workers at the University of Bern, Switzerland [29] . The following three items cover the factor of "therapeutic alliance" as perceived by the patient: (1) "The therapist and I understand each other", (2) "Today I felt at ease with the therapist", and (3) "I think the therapist is really interested in my wellbeing". The statements are rated on a 7-point Likert scale anchored by -3, "absolutely not true", 0, "neither nor", and +3, "absolutely true".
In this article we use the TONES study to exemplify how linear mixed models according to the approach of [23] can be used for designing and analyzing a randomised trial.
The factors taken into account were therapy (CBT versus CR) and center (1 versus 2 versus 3) as examples for level 2 (time-invariant) factors. At level 1 (time-variant factors) the following factors were used: time (12 monthly measurements during a period of 0-11 months), at least one session visited in the time interval between the last and the actual rating of negative symptoms (yes versus no), and the factor "therapeutic alliance" from the BPSR-P. Singer and Willet (2003) [23] proposed building up the model by estimating individual regression parameters for each subject followed by the estimation of mean parameters out of these individual ones. Intercept and slope are considered as random effects due to the fact that in the next sample other subjects are included, and an unstructured covariance matrix is assumed. This approach facilitates insight into the model building in terms of the variance components. Only after having built and checked the whole model according to this principle it is finalized using a repeated measurement approach, as demonstrated below.
First the null model is tested. This model has no independent factor and therefore calculates the individual mean and the individual and overall deviation from this mean.
Null model:
Where i = patient 1 to i and j = measurement 0 to j 00 = overall mean 0i = difference between person specific mean and overall mean ij = difference between individual measurement and person specific mean If there is enough variation between the subjects, and normal distribution is verified, the next step is to check the unconditional growth model. In this model, time is the only independent factor that is analyzed for its influence.
Unconditional growth model:
Where i and j as above. 
Where i and j as above ) in the unconditional growth model according to Gruber (1982) [30] , the model analyzing the influence of fixed factors (in our case: the two therapies and adjustment for centers) is built.
Standard Model:
Y ij = 00 + 10 * time ij + 01 * X i + 11 * X i * time ij
Where i, j, 00 , 0i , 00 , 0i and ij as above
Pseudo-R 2 statistics are calculated using the equations below and indicate the degree of explanation that an additional independent factor can contribute to the variability at this level.
Residual of level 1:
Residuals of level 2:
2 (unconditional growth model)
The final model built by means of this approach is then re-analyzed by a model that takes the repeated structure of the data into account and models the variance matrix properly. Models are compared by using the AIC (Akaike's information criterion) and BIC (Bayesian information criterion). This re-analysis can be regarded as a means of making final adjustments of the regression parameters.
A requirement of linear mixed models is the normal distribution of the composed residual
According to Hox (2002) [2] , the residuals of the null model and the residuals of the final model were evaluated graphically for normal distribution. Calculating the same model with robust standard errors, and a second time with asymptotical ones, allows one to assess whether a possible deviation from normal distribution affects the results, as has been shown [31, 32] .
Effect sizes for the primary endpoint were estimated using Hedges' g [33] adjusted for sample size.
with 
with
L / U : lower/upper limit of confidence interval C /2 : critical value of standard normal distribution
Based on the argument posed [34] , the standard deviation of the baseline values was used for s E / s C .
In addition to the fixed factors the aforementioned time-variant factors were exemplified. Their influence is on the individual level. Therefore changes in the level 1 variance component are considered.
Models were built up using SAS 9.1. Macros are available from the author.
RESULTS
The linearity of the dependent variable "MNSscore", i.e. the severity of negative symptoms, over the 10 assessments was checked by graphs of single individuals and the mean course. The observed course was compatible with the assumption of linearity.
The null model according to formula (1) revealed enough variation within as well as between patients and a sufficient fit to normal distribution. The unconditional growth model (formula 2) demonstrated a linear change over the time of the study, different from zero, a heteroscedasticity according to formula (3) between 0.64 and 0.86 and an autocorrelation (formula 4) between 0.79 and 0.9 at the different time points. The factor time explains about 35% of the individual variability at level 1, estimated as pseudo-R 2 statistic of level 1 residuals (formula 6). Building up the standard model according to formula (5) (12) No influence of the therapy on the intercept was assumed due to the fact that only the part modeling the slope (y 11 * Centre i *Therapy i * time ij ) included the factor "therapy". This model explains 34% of the variability of the slopes but only 1.5% of the variability of the intercepts, i.e. of the variability of the groups at level 2, according to formula (7).
As shown in Figure 1 , a strong interaction was found between center and therapy.
After having built this final model, with intercept and slope as random effects, and assuming an unstructured covariance matrix, the model was reanalyzed as a model with repeated measurements for which a Toeplitz covariance structure revealed the best results. Table 1 shows the results and corresponding effect sizes (calculated according to formula 9, 10 and 11) for the primary endpoint "difference in negative symptoms between therapy groups".
CBT revealed the anticipated success in the treatment of negative symptoms only in one center, the overall effect size of CBT over all centers being lower by only 0.12 points for negative symptoms after CR. Therefore the explorative search for subgroups that might especially benefit from this therapy started. No fixed effects were found for characterizing a special subgroup (data not shown). Therefore time varying factors came into the focus. It was assumed that the actual attendance by a patient of the therapy session would influence the success of these therapies. At least one session had to be attended in the time interval between the last and the actual rating of negative symptoms, in order for it to be counted as "treated in this interval". Although it seems obvious that "no therapy" meant "no progression", the model mirroring this assumption did not prove to be the best one with regard to the negative symptoms. The best model according to AIC and BIC criterion was the following, Figure 2 shows the resulting curves. Despite the interpretation of time invariant effects like therapy or sex, the curves for time varying effects do not represent real characteristics. There may be patients that visited all their therapy sessions, but there may be patients that visited none of them. The mean patient will switch more or less often between the two curves. Therefore the two curves are only the marginal conditions of the real individual curves. The difference between the two curves is small (0.11 points), and the fact that the curve for "no therapy in the preceding interval" also decreases, reveals a longer lasting effect of previous sessions. Nevertheless, there was no difference between therapies and no explanation for the interaction of centers with therapy groups.
Therefore the therapeutic alliance rating of each patient assessed at the end of each therapy session, was taken into account. The therapeutic alliance was elicited via different items ranging from -3 (not at all) to +3 (absolutely) and varied from one assessment to the next. Whether a time varying factor is dichotomous or ordinal does not change the analysis but complicates the interpretation of the results as Figure 3 shows (curves representing negative emotional engagement are missing because this did not occur). Again, the curves only mark the marginal conditions. Due to the fact that the therapeutic alliance may change from one session to the next, each patient has his own real curve, switching between these marginal conditions. Figure 3 reveals that the more successful the therapy, the less positive the patient's alliance rating. But, again, a strong interaction between therapy and center plays a role in the background. This result only holds true for two centers. In the third center, therapeutic alliance did not matter at all, as wide ranging success was observed.
No difference was observed with regard to the composition of the patient groups in a given center which explained the interaction between therapy and center. Due to this fact we assumed, that differences were linked to therapists, because most centers had only one or two therapists. To explore this, a patients' estimations of his or her therapist were assessed over the whole course of the study. A subgroup of patients could be found with at least two of the three following characteristics: emotional engagement always between 0.5 and 2 points, satisfaction with therapy between 0 and 1 point and possibility of co-management of therapy between 0 and 1. This subgroup revealed an overall effect of CBT compared to CB of 0.3 points (see Figure 4) , which is close to the expected 0.35 points. But, again, a strong interaction was found, when integrating the factor "center" into the analysis (see Table 2 ). In this subgroup, however, CBT revealed an improvement of negative symptoms for two of the three centers.
The flow chart presented in Figure 5 indicates, how a model can be built, when to check for model assumptions, when to include time-invariant and timevariant effects and how to finalize the model.
DISCUSSION
Through the TONES study, we show how linear mixed models can be used in clinical trials. This method offers great advantages as it can be used to analyze time-variant factors and to model specific assumptions like identical intercepts -or even slopesin subgroups. By adopting the approach of Singer and Willett [23] , better insight into model building can be achieved, as compared to starting with a repeated measurements model.
A major advantage of this method is the transparent and statistically specified handling of missing values, being estimated automatically by the method itself and results obtained by incomplete datasets are only slightly different from those obtained with complete datasets [37] .
Sophisticated imputation methods, which were again proposed recently [35, 36] are superfluous. By comparing different methods for dealing with missing data, [38] also concluded that the best method involved mixed models because imputations can be dispensed with. Only when the sample size is small, and when there are many time points and a great proportion of missing data, did the multiple imputation method appear to be better than mixed models [38] .
When using linear mixed models there is no need for identical intervals between the assessments for all patients, as the method estimates an individual curve for each subject. In the case of individual measurement intervals, only the re-analysis as repeated measurements model and the adjustment of the covariance structure are omitted.
Through linear mixed models, the sample size is minimized as compared to an analysis of covariance, due to the fact that the correlation between the data is taken into account. Although sample size calculation for linear mixed models is not yet implemented in standard software, the equation proposed [2] , according to Kish (1987) [39] , may be used for a calculation of sufficient precision: n eff = n / 1+ (n clus 1) [ ]
With n clus = number of measurements per patient, n = number of data collected and = autocorrelation between measurements, the effective sample size can be calculated. According to Willett and Singer (1998) [40] n clus of between 8 to 10 is a good choice for modeling linear courses with an acceptable standard error.
Otherwise the sample size needed for analyzing a specific difference can be calculated by means of covariance analysis in a standard sample size calculation. By converting the equation above, the sample size needed for an analysis with linear mixed models can be calculated.
The use of mixed models in small sample N-of-1-designs was discussed recently [41] .
Further fields of application for mixed models were evaluated recently, such as for reliability studies, as [42] demonstrated, according to the proposals of [43, 44] or for their use in discriminant analysis, as proposed [45] . Their application in genome-wide association studies was also been discussed [46, 47] and linear mixed models were also used for the analysis of non-linear data, modeling them for example as exponential growth or fractional polynomial curves, as done [48, 49] .
These recent applications still lack user-friendly methods that fullfill all the requirements relevant to the context of planning and analyzing clinical studies.
Through the linear mixed models described here, we demonstrate their applicability for analyzing longitudinal data from clinical trials and show that important requirements in this context, such as sample size considerations and effect sizes, can be met. Thus, it is no longer necessary to apply inappropriate methods, such as covariance analysis or t-tests, at least in terms of linear longitudinal data.
However the GCP-compliance of linear mixed models for the confirmatory analysis of longitudinal data in clinical trials is under discussion. As shown the longitudinal data analysis using linear mixed modelling is a step-by-step procedure where every next step depends on the results of the analysis of the previous step. Therefore an analysis using linear mixed models is more or less data driven. This is in contradiction to the statistical principles of analysing clinical trials in the context of GCP [50] which prefers a detailed statistical analysis plan which must be fixed without any impression from real study data.
